Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -89.1%. (2009–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $15M | $15M | $13M | $17M | $9M | $2M | $678697 | $5M | $85162 | $208672 | — |
| Enterprise Value | $34M | $34M | $24M | $25M | $67808 | $29M | $32M | $24M | $16M | $10M | — |
| P/E Ratio → | -0.43 | — | — | — | — | — | 0.83 | — | — | — | — |
| P/S Ratio | 0.23 | 0.23 | 0.24 | 0.32 | 0.17 | 0.04 | 0.01 | 0.12 | 0.00 | 0.01 | — |
| P/B Ratio | 0.44 | 0.82 | 0.52 | 0.47 | 0.22 | 0.51 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.53 | 0.45 | 0.48 | 0.00 | 0.52 | 0.58 | 0.60 | 0.43 | 0.32 | — |
| EV / EBITDA | — | — | — | — | — | — | 10.31 | 171.52 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | 8.04 | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 12.1% | 12.1% | 7.9% | 8.1% | 11.8% | 14.8% | 14.5% | 9.2% | 6.5% | 6.5% | 8.9% |
| Operating Margin | -25.3% | -25.3% | -28.6% | -40.9% | -14.8% | -8.1% | 4.9% | -0.6% | -3.3% | -16.2% | -3.0% |
| Net Profit Margin | -29.3% | -29.3% | -29.7% | -34.7% | -27.5% | -14.2% | 1.5% | -8.3% | -24.4% | -20.7% | -8.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -89.1% | -89.1% | -53.4% | -49.0% | -62.8% | -7289.2% | — | — | — | — | — |
| ROA | -32.0% | -32.0% | -26.9% | -27.7% | -23.5% | -17.1% | 2.4% | -14.8% | -57.8% | -90.0% | -31.8% |
| ROIC | -33.7% | -33.7% | -28.9% | -43.3% | -18.0% | -11.6% | 10.2% | -1.5% | -9.8% | -103.0% | -20.8% |
| ROCE | -59.3% | -59.3% | -44.3% | -49.6% | -22.7% | -31.2% | 104.5% | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.08 | 1.08 | 0.48 | 0.34 | 0.30 | 6.19 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | 10.30 | 138.93 | — | — | — |
| Net Debt / Equity | — | 1.05 | 0.47 | 0.24 | -0.22 | 6.13 | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | 10.10 | 138.65 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -6.30 | -6.30 | -14.99 | -20.40 | -2.29 | -1.19 | 1.43 | -0.80 | -0.33 | -2.79 | -1.91 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.00 | 1.00 | 0.99 | 1.51 | 2.58 | 1.33 | 1.19 | 0.75 | 0.82 | 0.69 | 0.54 |
| Quick Ratio | 0.85 | 0.85 | 0.82 | 1.31 | 2.42 | 1.23 | 1.09 | 0.63 | 0.68 | 0.47 | 0.45 |
| Cash Ratio | 0.02 | 0.02 | 0.01 | 0.16 | 0.95 | 0.01 | 0.02 | 0.01 | 0.16 | 0.06 | 0.15 |
| Asset Turnover | — | 1.00 | 1.00 | 0.81 | 0.74 | 1.14 | 1.26 | 1.66 | 1.79 | 2.81 | 2.17 |
| Inventory Turnover | 9.93 | 9.93 | 11.51 | 10.24 | 12.86 | 15.22 | 14.38 | 10.37 | 10.83 | 9.07 | 13.26 |
| Days Sales Outstanding | — | 126.16 | 106.50 | 148.47 | 165.02 | 195.59 | 177.27 | 85.26 | 48.65 | 17.35 | 42.89 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | 48.4% | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | 120.8% | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% | 17.0% | 29.5% | 18.5% | 94.0% | 16.5% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 48.4% | 0.6% | 0.0% | 17.0% | 29.5% | 18.5% | 94.0% | 16.5% | — |
| Shares Outstanding | — | $30M | $19M | $12M | $2M | $656933 | $532311 | $530943 | $532264 | $511200 | $502592 |
Imminent liquidity and dilution
According to current market data, COSM trades at a price-to-sales ratio of 0.14, a valuation level that suggests investors are heavily discounting the company's future growth prospects due to persistent net losses and the absence of a clear path to positive earnings per share in the near term.
The extremely low P/S multiple relative to broader healthcare peers indicates that the market views the company as a speculative entity rather than a stable distributor. This valuation implies that the market is pricing in significant execution risk regarding the transition to higher-margin proprietary brands, as the current revenue base is not yet supported by meaningful profitability.
Based on reported financial statements, COSM's ROIC has remained consistently negative, reaching -20.8% in 2025Q4, which demonstrates that the company is currently destroying shareholder value rather than compounding it through its aggressive acquisition-led growth strategy in the European pharmaceutical distribution market.
The persistent negative return on invested capital suggests that the capital deployed into acquisitions and operational expansion is not generating sufficient returns to cover the cost of capital. Investors should monitor whether management can pivot toward organic growth, as the current trend indicates that capital allocation has been value-destructive.
As reported in recent quarterly filings, the company's cash conversion cycle has remained volatile, peaking at 105 days in 2023Q4 and settling at 61 days in 2026Q1, which highlights the structural difficulty of managing inventory and receivables within a low-margin wholesale distribution business model.
The extended DSO, which reached 110 days in 2026Q1, suggests that the company faces significant challenges in collecting payments from its retail pharmacy network. This inefficiency in working capital management directly exacerbates the company's liquidity constraints, as cash remains tied up in receivables rather than funding core operations.
According to historical balance sheet data, COSM's debt-to-equity ratio has climbed to 0.93 as of 2026Q1, indicating an increasing reliance on external financing to sustain operations as the company struggles to generate positive cash flow from its core pharmaceutical distribution activities.
The rising leverage profile is particularly concerning given the negative interest coverage ratios, which suggest that the company may struggle to service its debt obligations without further capital raises. This trend warrants close monitoring, as the company's ability to refinance existing debt may be limited by its current financial performance.
Investors frequently misapply top-line revenue growth as a primary indicator of health for COSM, failing to recognize that in a low-margin distribution model, such growth often masks underlying operational inefficiencies and the rapid depletion of cash reserves required to support the expanded scale.
The focus on revenue growth obscures the reality that the company's gross margins are insufficient to cover fixed operating costs, leading to persistent net losses. A more appropriate metric for this business model would be the 'cash-burn-to-revenue' ratio, which would better highlight the sustainability of the current growth trajectory.
Includes 30+ ratios · 17 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying COSM stock.
Cosmos Health Inc.'s current P/E ratio is -0.4x. The historical average is 0.8x.
Cosmos Health Inc.'s return on equity (ROE) is -89.1%. The historical average is -58.0%.
Based on historical data, Cosmos Health Inc. is trading at a P/E of -0.4x. Compare with industry peers and growth rates for a complete picture.
Cosmos Health Inc. has 12.1% gross margin and -25.3% operating margin.